Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASBP
Aspire Biopharma
$0.29
+2.4%
$0.00
$0.22
$15.80
$14.46M0.743.62 million shs607,517 shs
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$2.13
+4.4%
$2.06
$1.55
$5.59
$14.95M0.39494,089 shs2,671 shs
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$1.95
-1.5%
$2.81
$1.75
$39.38
$14.35M5.3199,142 shs29,428 shs
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
$0.73
$0.93
$2.22
$13.10
$3.75MN/A108,185 shs22,784 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASBP
Aspire Biopharma
0.00%+2.64%-23.26%+29,199,900.00%+29,199,900.00%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
0.00%+3.90%+16.39%-2.29%-50.43%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
0.00%+5.41%-27.78%-30.26%-93.07%
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
0.00%0.00%0.00%0.00%-51.60%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ASBP
Aspire Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
1.0448 of 5 stars
2.03.00.00.00.61.70.6
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ASBP
Aspire Biopharma
0.00
N/AN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
4.00
Strong Buy$5.00134.74% Upside
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
0.00
N/AN/AN/A
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RWOD, EDSA, ASBP, and ERNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$5.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ASBP
Aspire Biopharma
N/AN/AN/AN/A($2.17) per shareN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/A$0.61 per shareN/A
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$580K24.74N/AN/A$0.50 per share3.90
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ASBP
Aspire Biopharma
-$12.54MN/A0.00N/AN/AN/A-508.70%N/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$6.17M-$1.59N/AN/AN/AN/A-187.01%-78.72%8/8/2025 (Estimated)
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-$44.54M-$8.31N/AN/A-7,652.75%N/A-285.71%8/11/2025 (Estimated)
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A

Latest RWOD, EDSA, ASBP, and ERNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q2 2025
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$0.30-$0.30N/A-$0.30N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ASBP
Aspire Biopharma
N/AN/AN/AN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/AN/A
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/AN/AN/AN/AN/A
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ASBP
Aspire Biopharma
N/A
0.22
0.22
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/A
15.72
15.72
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/A
0.21
0.21
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
ASBP
Aspire Biopharma
19.17%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
5.50%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
70.55%
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
20.07%

Insider Ownership

CompanyInsider Ownership
ASBP
Aspire Biopharma
48.00%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
22.60%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
4.49%
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
2.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
ASBP
Aspire Biopharma
N/A49.53 million25.75 millionN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
207.02 million5.44 millionNot Optionable
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
107.36 million7.03 millionNo Data
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
N/A5.17 million5.06 millionNot Optionable

Recent News About These Companies

Redwood Services Makes 19th Acquisition
Redwood Announces Investment by Atlas Partners
Blank-Check Company Cal Redwood Files for IPO
Redwood Empire Whiskey Acquires Luxury Northern California Distillery
Acacia Capital buys Redwood City apartments for $184M
BMW of North America partners with Redwood Materials

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aspire Biopharma NASDAQ:ASBP

$0.29 +0.01 (+2.38%)
As of 07/3/2025 01:00 PM Eastern

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

Edesa Biotech stock logo

Edesa Biotech NASDAQ:EDSA

$2.13 +0.09 (+4.41%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$2.13 0.00 (0.00%)
As of 07/3/2025 04:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Ernexa Therapeutics stock logo

Ernexa Therapeutics NASDAQ:ERNA

$1.95 -0.03 (-1.52%)
Closing price 07/3/2025 01:36 PM Eastern
Extended Trading
$1.95 0.00 (0.00%)
As of 07/3/2025 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Redwoods Acquisition stock logo

Redwoods Acquisition NASDAQ:RWOD

Redwoods Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. In intends to focus on businesses in the carbon neutral and energy storage industries. The company was incorporated in 2021 and is based in New York, New York.